Dare Biosciences, Inc. was notified by Nasdaq Listing Qualifications Staff that its common stock is subject to delisting because the company's stockholders' equity was less than $2.5 million as of the period ended March 31, 2026, and it failed to meet alternative listing requirements. The company intends to request a hearing before a Nasdaq Hearing Panel to stay the suspension and delisting. Dare Biosciences, Inc. is a biotechnology company focused on developing and commercializing women's health products.
